Search research articles
Contact Us
Filters
Showing results (41-50 of 223) with videos related to
Page
of 23
Sort By:
Blood
|
November 5, 2005
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
Jan A Burger, Thomas J Kipps
Expert Opinion on Investigational Drugs
|
November 11, 2017
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
Philip A Thompson, Jan A Burger
Leukemia & Lymphoma
|
February 22, 2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Jan A Burger, Joseph J Buggy
Seminars in Cancer Biology
|
September 28, 2011
The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies
Jan A Burger, Richard J Ford
Cancer Research
|
May 27, 2010
BCR-mediated decrease of CXCR4 and CD62L in CLL
Maite P Quiroga, Jan A Burger
Blood
|
February 4, 2017
HSP90, a chaperone that can make you SYK
Elisa Ten Hacken, Jan A Burger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2013
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor
Elisa ten Hacken, Jan A Burger
Expert Opinion on Investigational Drugs
|
April 2, 2009
CXCR4 chemokine receptor antagonists: perspectives in SCLC
Jan A Burger, David J Stewart
Seminars in Cancer Biology
|
September 11, 2013
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies
Jan A Burger, John G Gribben
Open Journal of Hematology
|
July 31, 2012
Cell Trafficking in Chronic Lymphocytic Leukemia
Matthew S Davids, Jan A Burger
Page
of 23
Search research articles
Search
Showing results (41-50 of 223) with videos related to
Sort By:
Page
of 23
Blood
|
November 5, 2005
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
Jan A Burger, Thomas J Kipps
Expert Opinion on Investigational Drugs
|
November 11, 2017
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
Philip A Thompson, Jan A Burger
Leukemia & Lymphoma
|
February 22, 2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Jan A Burger, Joseph J Buggy
Seminars in Cancer Biology
|
September 28, 2011
The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies
Jan A Burger, Richard J Ford
Cancer Research
|
May 27, 2010
BCR-mediated decrease of CXCR4 and CD62L in CLL
Maite P Quiroga, Jan A Burger
Blood
|
February 4, 2017
HSP90, a chaperone that can make you SYK
Elisa Ten Hacken, Jan A Burger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2013
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor
Elisa ten Hacken, Jan A Burger
Expert Opinion on Investigational Drugs
|
April 2, 2009
CXCR4 chemokine receptor antagonists: perspectives in SCLC
Jan A Burger, David J Stewart
Seminars in Cancer Biology
|
September 11, 2013
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies
Jan A Burger, John G Gribben
Open Journal of Hematology
|
July 31, 2012
Cell Trafficking in Chronic Lymphocytic Leukemia
Matthew S Davids, Jan A Burger
Page
of 23